EGFR

[npj Breast Cancer] To find metastatic recurrence biomarkers of TNBC treated by neoadjuvant chemotherapy and anti-EGFR antibodies, investigators evaluated tumor genomic, transcriptomic, and immune features, using MSK-IMPACT assay, gene arrays, Nanostring technology, and TIL assessment on H&E.

[Proceedings of the National Academy of Sciences of the United States of America] Using a combination of in vitro and in vivo assays, scientists demonstrate that Tspan6 functioned as a tumor suppressor in colorectal cancer by attenuating the epidermal growth factor receptor–based signaling axis.

[Scientific Reports] Scientists identified three out of four datasets comparing erlotinib-sensitive and -resistant non-small cell lung cancer (NSCLC) cells which revealed an altered expression of KCa3.1 mRNA in erlotinib-resistant NSCLC cells.

[Scientific Reports] Investigators identified how circulating low-density lipoprotein (LDL) cholesterol and tumor LDL receptor (LDLR) may have accelerated oncogenic processes by determining whether increased LDLR expression and cholesterol uptake were associated with the activation of the epidermal growth factor receptor (EGFR) signaling pathway in TNBC cell lines.

[HUTCHMED, Ltd.] HUTCHMED Limited and AstraZeneca PLChave initiated SANOVO, a China Phase III study of ORPATHYS®, an oral, potent, and highly selective MET tyrosine kinase inhibitor, in combination with AstraZeneca’s third-generation, irreversible epidermal growth factor receptor (EGFR) TKI, TAGRISSO® as a first-line treatment in certain non-small cell lung cancer patients whose tumors harbor EGFR mutation and overexpress MET.

[Genome Medicine] Whole-exome and total RNA sequencing was performed on 137 samples from 121 microsatellite stable colorectal cancers, including multiregional samples of primary and metastatic tumors from 4 patients.